Previous 10 | Next 10 |
The FDA has granted Breakthrough Therapy Designation for CymaBay Therapeutics' (NASDAQ: CBAY ) seladelpar for the treatment of early stage primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, or as monotherapy in...
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in com...
Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL ) +3.3% after-hours as Gilead’s (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic...
Genfit SA ( OTCPK:GNFTF ) initiated with Buy rating and a €46 (144% upside) price target at B. Riley FBR citing an expected positive outcome from the Phase 3 RESOLVE-IT study evaluating elafibranor in NASH. More news on: Genfit, CymaBay Therapeutics, Vertex Pharmaceuticals Incorpora...
Author’s note: I am grateful to President & CEO, Mr. Sujal Shah for granting me the call interview for this article. Introduction CymaBay Therapeutics ( CBAY ) is a small cap ($567M) clinical-stage biopharma developing innovative therapeutics for rare/orphan diseases and chr...
NEWARK, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal Shah, President and Chief Executive O...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
Recent filings for planned equity offerings from healthcare companies: More news on: Vaxart, Inc., Bio-Path Holdings, Inc., Hemispherx Biopharma, Inc, Healthcare stocks news, Stocks on the move, Consumer stocks news, Read more ...
NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcomi...
CymaBay Therapeutics, Inc. (CBAY) Q3 2018 Earnings Conference Call November 6, 2018 4:30 PM ET Executives Dan Menold – Vice President-Finance Sujal Shah – Chief Executive Officer Pol Boudes – Chief Medical Officer Chuck McWherter – Chief Scientific O...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...